Visitation Alert


Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

  • Clinical Trial Information

    Trial Contact: Spinelli, Jennifer; Leffin, Melissa; El-Shami, Jessica

  • IRB No: APEC1621G

    Protocol Abbrev: APEC1621G

    Principal Investigator: Amy A Smith, MD

    Phase: Drug: Phase II

    Age Group: Pediatric

    Secondary Protocol No: APEC1621G

    Treatment: vemurafenib

    Therapies Involved: Chemotherapy ID: NCT03220035

  • Objective

    To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with vemurafenib with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating BRAF V600 mutations.

  • Key Eligibility

    Inclusion Criteria:
    Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
    Sexes Eligible for Study: All
    Accepts Healthy Volunteers: No